Facebook Linkedin RSS Twitter Youtube
Home 2024

Obesity

StockWatch: Challengers Take Aim at Lilly, Novo Nordisk
Drug Discovery

StockWatch: Challengers Take Aim at Lilly, Novo Nordisk

Novo Nordisk Expands Boston Area Research and Early Development
Drug Discovery

Novo Nordisk Expands Boston Area Research and Early Development

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment
Drug Discovery

With $170M, BioAge Joins Lilly in Oral, Muscle Preserving Obesity Treatment

StockWatch: Lilly’s Weighty Q4 Results Impress Investors, Analysts
Drug Discovery

StockWatch: Lilly’s Weighty Q4 Results Impress Investors, Analysts

Novo Holdings Buys Catalent for $16.5B; Sells Three Sites to Novo Nordisk for $11B
Bioprocessing

Novo Holdings Buys Catalent for $16.5B; Sells Three Sites to Novo Nordisk for $11B

StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs
Cancer

StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs

Obesity Held Back by Single Gene Deletion, Reversing Mitochondrial Fission in Mice
Featured

Obesity Held Back by Single Gene Deletion, Reversing Mitochondrial Fission in Mice

A16z’s Vijay Pande Weighs in on M&A Activity, Obesity Drugs, Gene Editing, and AI
Artificial Intelligence

A16z’s Vijay Pande Weighs in on M&A Activity, Obesity Drugs, Gene Editing, and AI

Gut-Brain Circuits For Sugar and Fat Cravings Combine to Trigger Overeating
Featured

Gut-Brain Circuits For Sugar and Fat Cravings Combine to Trigger Overeating

StockWatch: Analysts Weigh Obesity Drug Market Pegged at $100B by 2030
Drug Discovery

StockWatch: Analysts Weigh Obesity Drug Market Pegged at $100B by 2030

1234...54Page 3 of 54
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.